

1 **Intragenic recruitment of NF- $\kappa$ B drives alternative splicing modifications upon**  
2 **activation by the viral oncogene TAX of HTLV-1.**

3

4 Lamya Ben Ameer<sup>1</sup>, Morgan Thenoz<sup>1,2,\$</sup>, Guillaume Giraud<sup>1, \$</sup>, Emmanuel Combe<sup>1</sup>, Jean-  
5 Baptiste Claude<sup>1</sup>, Sebastien Lemaire<sup>1</sup>, Nicolas Fontrodona<sup>1</sup>, H  l  ne Polveche<sup>3</sup>, Marine  
6 Bastien<sup>1,4</sup>, Antoine Gessain<sup>5</sup>, Eric Wattel<sup>6</sup>, Cyril F. Bourgeois<sup>1</sup>, Didier Auboeuf<sup>1,\*</sup> and  
7 Franck Mortreux<sup>1,\*</sup>.

8

9

10 1. Univ Lyon, ENS de Lyon, Univ Claude Bernard, CNRS UMR 5239, INSERM U1210,  
11 Laboratory of Biology and Modelling of the Cell, 46 All  e d'Italie Site Jacques Monod, F-  
12 69007, Lyon, France

13

14 2. Faculty of Medicine and Health Sciences Department of Pediatrics and medical  
15 genetics, 9000 Gent, Belgium

16

17 3. CECS, I-Stem, Corbeil-Essonnes, 91100, France

18

19 4. School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University,  
20 Liverpool, United Kingdom

21

22 5. Unit   d'  pid  miologie et Physiopathologie des Virus Oncog  nes, Institut Pasteur,  
23 Paris, France.

24

25 6. Universit   Lyon 1, CNRS UMR5239, Oncovirologie et Bioth  rapies, Facult   de  
26 M  decine Lyon Sud, ENS - HCL, Pierre B  nite, France; Universit   Lyon I, Service  
27 d'H  matologie, Pavillon Marcel B  rard, Centre Hospitalier Lyon-Sud, Pierre B  nite,  
28 France.

29

30 \$ These authors contributed equally

31 \* corresponding authors

## Summary

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

The chronic NF- $\kappa$ B activation in inflammation and cancer has long been linked to persistent activation of NF- $\kappa$ B responsive gene promoters. However, NF- $\kappa$ B factors such as RELA also massively bind to gene bodies. Here, we demonstrate that the recruitment of RELA to intragenic regions regulates alternative splicing upon activation of NF- $\kappa$ B by the viral oncogene TAX of HTLV-1. Integrative analysis of RNA splicing and chromatin occupancy, combined with chromatin tethering assays, demonstrate that DNA-bound RELA interacts with and recruits the splicing regulator DDX17 in a NF- $\kappa$ B activation-dependent manner, leading to alternative splicing of target exons thanks to DDX17 RNA helicase activity. This NF- $\kappa$ B/DDX17 axis accounts for a major part of the TAX-induced alternative splicing landscape that mainly affects genes involved in oncogenic pathways. Collectively, our results demonstrate a physical and direct involvement of NF- $\kappa$ B in alternative splicing regulation, which significantly revisits our knowledge of HTLV-1 pathogenesis and other NF- $\kappa$ B-related diseases.

Keywords : NF- $\kappa$ B, alternative splicing, HTLV-1, viral oncogenesis.

## 1 **Introduction**

2 The Human T-cell leukemia virus (HTLV-1) is the etiologic agent of Adult T-cell  
3 Leukemia/Lymphoma (ATLL) <sup>1</sup>, an aggressive CD4+ T-cell malignancy, and of various  
4 inflammatory diseases including the HTLV-1-associated myelopathy/tropical spastic  
5 paraparesis (HAM/TSP) <sup>2</sup>. It has long been established that changes in gene expression  
6 level participate to the persistent clonal expansion of HTLV-infected CD4+ and CD8+ T-  
7 cells, leading ultimately to HTLV-1 associated diseases <sup>3</sup>. We recently reported that  
8 alternative splicing events help to discriminate between ATLL cells, untransformed  
9 infected cells and their uninfected counterparts derived from patients <sup>4</sup>. Alternative  
10 splicing of pre-messenger RNAs is a cotranscriptional processing step that controls both  
11 the transcriptome and proteome diversity and governs in turn cell fate. Its regulation  
12 relies on a complex and still incompletely understood interplay between splicing factors,  
13 chromatin regulators and transcription factors <sup>5,6</sup>. In this setting, the molecular  
14 mechanisms of HTLV-1-induced splicing modifications and whether these effects rely on  
15 an interplay between transcription and splicing is not known .

16  
17 TAX is an HTLV-1-encoded protein that regulates viral and cellular gene transcription.  
18 TAX also alters host signaling pathways that sustain cell proliferation and lead ultimately  
19 to cell immortalization <sup>7</sup>. The Nuclear factors  $\kappa$ B (NF- $\kappa$ B) signaling pathway is the most  
20 critical target of TAX for cell transformation <sup>8</sup>. The NF- $\kappa$ B transcription factors (RELA, p50,  
21 c-Rel, RelB, and p52) govern immune functions, cell differentiation and proliferation <sup>9</sup>. NF-  
22  $\kappa$ B activation involves the degradation of I $\kappa$ B that sequesters NF- $\kappa$ B factors in the  
23 cytoplasmic compartment, leading to NF- $\kappa$ B nuclear translocation and binding of NF- $\kappa$ B  
24 dimers (e.g., RELA:p50 for the most abundant) to their target promoters <sup>10,11</sup>. TAX induces  
25 IKK phosphorylation and I $\kappa$ B degradation, leading to persistent nuclear translocation of  
26 NF- $\kappa$ B <sup>12,13</sup>. In addition, TAX interacts with nuclear NF- $\kappa$ B factors and enhances their  
27 effects on transcription <sup>14,15</sup>.

28  
29 Interestingly, genome-wide analyses of NF- $\kappa$ B distribution have unveiled that the vast  
30 majority of RELA peaks is outside promoter regions and can be localized in introns and  
31 exons <sup>16-19</sup>. Some of those promoter-distant RELA binding sites correspond to *cis*-  
32 regulatory transcriptional elements <sup>20,21</sup> but globally, there is a weak correlation between  
33 the binding of RELA to genes and regulation of their steady-state expression <sup>17,18</sup>. These

1 data suggest that NF- $\kappa$ B could have other functions than its initially described  
2 transcription factor function.

3

4 Here, we show for the first time that NF- $\kappa$ B activation accounts for alternative splicing  
5 modifications generated upon TAX expression. These effects rely on a tight physical and  
6 functional interplay between TAX, RELA and the DDX17 splicing factor. Our results reveal  
7 that DNA binding of RELA at the vicinity of genomic exons regulates alternative splicing  
8 through the recruitment of DDX17, which modulates exon inclusion thanks to its RNA  
9 helicase activity.



## 1 **Results**

### 2 **TAX induces alternative splicing modifications irrespectively of its effects on** 3 **transcription.**

4 RNA-seq analyses were performed on 293T-LTR-GFP cells transiently transfected with a  
5 TAX expression vector. TAX-induced changes in gene expression level and in alternative  
6 splicing were identified and annotated as previously described<sup>22,23</sup>(Table S1). As shown  
7 in Figure 1A, the ectopic expression of TAX affected the splicing and gene expression  
8 levels of 939 and 523 genes, respectively. A total of 1108 alternative splicing events were  
9 predicted including 710 exon skipping events (Figure 1B). A minority of genes (3.5%,  
10 33/939) was altered at both the expression and splicing levels, indicating that TAX largely  
11 affects alternative splicing independently of its transcriptional activity. A subset of  
12 splicing events was validated by RT-PCR (Figure 1C). We took advantage of RNA-seq  
13 datasets (EGAS00001001296<sup>24</sup>) for assessing whether TAX-related alternative splicing  
14 could pertain to asymptomatic carriers (AC) and ATLL patients. Overall, 542 (48%) TAX-  
15 induced splicing modifications were detected at least once across 55 clinical samples  
16 (Table S1). Hierarchical clustering of these exons based on their inclusion rate (PSI)  
17 identified TAX-regulated exons that discriminate AC and ATLL samples from uninfected  
18 CD4+ T-cells (Figure 1D). We furthermore confirmed that TAX promotes splicing events  
19 previously detected in HTLV-1 infected individuals, including *AASS*, *CASK*, *RFX2* and *CD44*  
20<sup>4,25</sup>. We firmly established that the expression of the splicing variant *CD44v10* previously  
21 identified in HAM/TSP patients<sup>25</sup> fully relies on TAX expression (Figure 1C and Figures  
22 S1A-C). Altogether, these results uncovered a large number of splicing modifications upon  
23 TAX expression that for a part coincide with alternative splicing events observed in HTLV-  
24 1 patients.

25  
26 Gene ontology analysis of quantitatively altered genes revealed several signaling  
27 pathways that are well described in TAX expressing cells, including NF- $\kappa$ B, TNF, and  
28 MAPK signaling (Figure 1E)<sup>26,27</sup>. In contrast, genes modified at the splicing level belong  
29 to membrane-related regulatory processes including focal adhesion and ABC transporters  
30 (Figure 1E). In this setting, we observed that TAX-expressing cells displayed switched cell  
31 adhesion properties from hyaluronate- to type IV collagen-coated surfaces, which is in  
32 accordance with the substrate affinity of the *CD44v10* isoform<sup>28</sup> (Figure S1D).

33

1 **The splicing factor DDX17 interacts with RELA and TAX in a NF- $\kappa$ B dependent**  
2 **manner.**

3 Since Tax is a well-known trans-acting transcription regulator, we first analysed whether  
4 TAX could affect gene expression levels of splicing factors. However, no significant change  
5 was measured for 227 genes encoding splicing regulators (Table S1, Figure 2A), thereby  
6 suggesting a direct role of TAX in alternative splicing regulatory mechanisms. To tackle  
7 this question, we focused on the auxiliary component of the spliceosome DDX17, which  
8 has been previously identified, but not validated, in a recent mass spectrometry screen  
9 for putative protein partners of TAX <sup>29</sup>.

10

11 We therefore aimed to validate the interaction between TAX and DDX17. As shown in  
12 Figure 2B, TAX co-immunoprecipitated with the two endogenous isoforms of DDX17,  
13 namely p72 and p82. Reciprocal IP confirmed this interaction (Figure 2C). Due to the  
14 involvement of NF- $\kappa$ B signaling in TAX positive cells (Figure 1D, <sup>27</sup>), we examined whether  
15 DDX17 interacts with a TAX mutated form, namely M22 (G137A, L138S), which is  
16 defective for IKK and NF- $\kappa$ B activation <sup>30-33</sup>. Despite similar expression levels and  
17 immunoprecipitation efficiencies of TAX and M22 (Figure 2D), we failed to detect any  
18 interaction between M22 and DDX17 (Figures 2B and 2C), suggesting that NF- $\kappa$ B is  
19 required for recruiting DDX17. In this setting, RELA co-immunoprecipitated with DDX17  
20 and TAX, but not with M22 (Figures 2B and 2C). Moreover, DDX17 was co-  
21 immunoprecipitated with RELA in a TAX-dependent manner (Figure 2E). This interaction  
22 did not require RNA since the DDX17:RELA complex remained detected when cell extracts  
23 were pre-treated with RNase A (Figure 2F).

24

25 As DDX17:RELA complexes were observed neither in control cells (that do not expressed  
26 TAX) nor in M22 expressing cells, this suggested that NF- $\kappa$ B activation is necessary for the  
27 binding of DDX17 to RELA. This hypothesis was confirmed by exposing TAXM22-  
28 expressing cells to TNF $\alpha$ , a potent NF- $\kappa$ B activator that allowed to retrieve DDX17:RELA  
29 complexes (Figure 2G). Altogether, these results revealed that TAX-induced NF- $\kappa$ B  
30 activation dynamically orchestrates the interactions between TAX, the transcription factor  
31 RELA and the splicing regulator DDX17 (Figure 2H).

32

33 **TAX-mediated effects on splicing depend on DDX5/17.**

1 To estimate the role of DDX17 in TAX-regulated splicing events, RNA-sequencing was  
2 performed using 293T-LTR-GFP cells expressing or not TAX and depleted or not for  
3 DDX17 and its paralog DDX5, which cross-regulate and complement each other<sup>22,34,35</sup>.  
4 TAX had no effect on the expression of DDX5 and DDX17 (Figures 2A and 3A) and RELA  
5 protein level was not significantly changed upon both TAX expression and *DDX5/17*  
6 silencing (Figure 3B).

7  
8 Overall, 58.5% (648/1108) of TAX-regulated exons were affected by *DDX5/17*  
9 knockdown, a significantly higher proportion than expected by chance (Figure 3C, Figure  
10 S2A). Of particular significance, 423 TAX-induced splicing events were completely  
11 dependent on the presence of DDX5/17 (Table S3). For example, *DDX5/17* silencing  
12 completely abolished the TAX-mediated effect on splicing of *SEC31B*, *CASK*, *MYCBP2*,  
13 *CCNL1*, *ROBO1*, *ADD3* and *CD44* transcripts (Figure 3D). Of note, splicing specific RT-PCR  
14 assays permitted to validate the effect of DDX5/17 on TAX-dependent splicing changes  
15 for *CD44*, *ADD3* and *EIF4A2* transcripts, even though their predicted differential inclusion  
16 fell below the arbitrary computational threshold (Table S3, Figure 3D and Figure S2D).  
17 This suggested that the contribution of DDX5/17 to TAX-mediated alternative splicing  
18 regulation might be under-estimated.

19  
20 Finally, since NF- $\kappa$ B activation modified the interactions between DDX17, RELA, and TAX  
21 (Figure 2), we examined the interplay between NF- $\kappa$ B activation and DDX17-mediated  
22 splicing regulation. As shown in Figure 3D, M22 did not have any effect on DDX5/17-  
23 sensitive splicing events, arguing that TAX splicing targets are regulated by RNA helicases  
24 DDX5/17 in an NF- $\kappa$ B dependent manner.

### 25 26 **RELA binds to genomic exons and recruits DDX17 to regulate splicing in an RNA** 27 **helicase-dependent manner.**

28 The results described above prompted us to hypothesize that the nuclear translocation of  
29 RELA upon TAX expression might promote the chromatin recruitment of DDX17 to RELA  
30 target genes. To test this hypothesis, the *CD44* gene was used as a gene model. *CD44* is  
31 composed of 10 constitutive exons and 10 variable exons. The constitutive exons 1–5 and  
32 15–20 encode the standard *CD44* transcripts, while *CD44* variants (*CD44v*) are produced  
33 by extensive splicing leading to alternative inclusion of variable exons 5a-14 also named

1 v1-v10 (Figure 4A) <sup>36</sup>. As shown above (Figure 3D), the exon v10 inclusion rate is  
2 markedly influenced by TAX in a DDX5/17- and NF- $\kappa$ B activation-dependent manner. The  
3 importance of NF- $\kappa$ B in this process was further confirmed as the inactivation of NF- $\kappa$ B  
4 *via* the ectopic expression of the I $\kappa$ B $\alpha$  super repressor (I $\kappa$ BSR) abolished the effects of  
5 TAX on *CD44* v10 inclusion (Figure S3A).  
6  
7 Quantitative ChIP (qChIP) analyses revealed that RELA was recruited upon TAX  
8 expression not only to the *CD44* promoter, but also to a genomic region spanning the  
9 alternative exon v10, but not a downstream constitutive exon (E16) (Figures 4A and 4B,  
10 left panel). To assess whether RELA occupancies at the v10 exon and *CD44* promoter are  
11 interrelated, a stable cell line was generated in which the  $\kappa$ B site localized at -218 bp from  
12 the transcription start site (TSS) was deleted using a CRISPR-Cas9 approach. Positive  
13 clones (*CD44* $\Delta$  $\kappa$ B) were screened and sequenced to confirm the 40 bp deletion in the  
14 promoter region (Figure 4A). As expected, TAX expression failed to promote RELA  
15 binding at the promoter in *CD44* $\Delta$  $\kappa$ B cells (Figure 4B, right panel). Nevertheless, TAX still  
16 promoted RELA binding at the v10 region. Importantly, TAX expression induced v10  
17 inclusion at a similar level in both *CD44* $\Delta$  $\kappa$ B and parental cells (Figure 4C). These results  
18 suggested that TAX-mediated effect on exon v10 splicing could depend on RELA binding  
19 in the vicinity of the alternative v10 exon. Supporting this hypothesis, the analysis of  
20 publicly available RELA ChIP-seq datasets revealed that intragenic RELA peaks are  
21 significantly closer to alternative exons than to constitutive exons (Figure S3B). In this  
22 setting, we observed that RELA binding sites are often found in the vicinity of TAX  
23 regulated exons (Figure 4D). Using the MEME-ChIP suite as motif discovery algorithm<sup>37</sup>,  
24 we uncovered that RELA-binding sites located within the closest range (<1kbp) of TAX-  
25 regulated exons coincided with the typical NF- $\kappa$ B consensus motif (Figure 4E).  
26 Furthermore, this subset of TAX-regulated exons displayed weak 3' and 5' splice sites  
27 together with significant low MFE value (Figure 4F) and high GC-content (Figure 4G)  
28 when compared to all human exons. This emphasizes the high potential of these splice  
29 sites to form stable secondary RNA structures, a typical feature of exons regulated by RNA  
30 helicases DDX5/17 <sup>34</sup>. Taken together, these data define a signature of splicing target  
31 specificity for RELA, and they suggest that RELA and DDX17 might control together the  
32 inclusion of a subset TAX-regulated exons. We therefore investigated the genomic  
33 occupancy of some target exons by RELA and DDX17 by qChIP analysis of cells expressing

1 or not TAX. For all tested genes (*CD44*, *SEC31B*, *CASK*, and *MYCBP2*), both RELA and  
2 DDX17 bound specifically the regulated alternative exon in a TAX-dependent manner,  
3 compared to a downstream constitutive exon (Figure 4H). Furthermore, RELA binding  
4 was lost in cells depleted for DDX5/17, indicating that RNA helicases contribute to  
5 stabilize DNA-bound RELA (Figure 4I).

6  
7 **A causal relationship between exonic DNA-binding of RELA, chromatin recruitment**  
8 **of DDX17, and splicing regulation.**

9 To assess the causative relationship that links RELA and DDX17 to alternative splicing, we  
10 intended to experimentally tether DDX17 or RELA at the *CD44* v10 exon locus using  
11 modified TALE (Transcription-Activator-Like-Effector) <sup>38</sup>. We designed a TALE domain  
12 that recognizes specifically an exonic 20 bp DNA sequence located 12 bp upstream from  
13 the 5' splice site (SS) of exon v10. This TALE domain was either fused to RELA or DDX17  
14 proteins (Figure 5). We also used an additional construct consisting in the same TALE  
15 fused to GFP to rule out non-specific effects resulting from the DNA binding of the TALE.  
16 Each TALE construct was transiently transfected into 293T-LTR-GFP cells, and we  
17 monitored their relative effects both on the recruitment of endogenous RELA and DDX17,  
18 and on the splicing of exon v10. All results shown in Figure 5 were normalized and  
19 expressed as relative effects compared to the TALE-GFP. As expected, and validating our  
20 approach, TALE-RELA tethering to the exon v10 led to a significant chromatin recruitment  
21 of RELA to its target site, and not to the downstream exon E16 used as control (Figure 5A,  
22 left panel). A significant and specific enrichment of DDX17 was also observed on exon v10  
23 upon expression of the TALE-RELA compared to TALE-GFP (Figure 5A, left panel),  
24 indicating that tethering RELA to exon v10 induced a local recruitment of endogenous  
25 DDX17 proteins. At the RNA level, this TALE-RELA-mediated recruitment of DDX17  
26 coincided with a significant increase in exon v10 inclusion rate (Figure 5A).

27  
28 We next investigated whether DDX17 tethering could result in similar effects.  
29 Quantitative ChIP analysis demonstrated that DDX17 was properly tethered to exon v10  
30 when fused to the designed TALE (Figure 5B) but TALE-DDX17 had no effect on RELA  
31 recruitment (Figure 5B). This was expected since the formation of RELA:DDX17  
32 complexes only occurs upon NF- $\kappa$ B activation (Figure 2). Nevertheless, TALE-DDX17-  
33 expressing cells exhibited a reproducible and significant increase in v10 inclusion (Figure

1 5B), indicating that chromatin-bound DDX17 alone can modulate splicing efficiency. It is  
2 worth to underline that the level of v10 exon inclusion induced by the TALE-RELA and -  
3 DDX17 was comparable to that measured in cells transiently transfected with a TAX  
4 expression vector (Figure 4C and Figure S1C). Although it is less quantitative approach, a  
5 nested RT-PCR assay clearly confirmed these results (Figure S4). Strikingly however, the  
6 TALE-DDX17\_K142R (a DDX17 helicase mutant <sup>34,39-41</sup>) failed to influence exon v10  
7 inclusion despite a clear chromatin enrichment of DDX17 (Figure 5C, Figure S4).  
8 Collectively, these results demonstrate that the binding of RELA at the vicinity of genomic  
9 exons recruits the RNA helicase DDX17 that positively regulates the inclusion rate of the  
10 target exon thanks to its RNA helicase activity.

## 1 **DISCUSSION**

2 Since the finding of splicing dysregulations in HTLV-1 infected individuals <sup>4,24,25,42</sup>,  
3 deciphering how HTLV-1 interferes with the splicing regulatory network has become a  
4 new challenging issue for improving our knowledge of HTLV-1 infection and its associated  
5 diseases. Here, we provide the first molecular evidence that upon TAX-induced NF- $\kappa$ B  
6 activation, RELA directly regulates splicing by binding to gene bodies at the vicinity of GC-  
7 rich exons and by locally recruiting the splicing factor DDX17, which regulates splicing via  
8 its RNA helicase activity.

9  
10 Our results demonstrate for the first time that TAX deeply impacts alternative splicing  
11 independently from its effects on transcription. In addition, TAX-regulated exons were  
12 found in transcripts enriched in functional pathways that are distinct from those enriched  
13 by TAX transcriptional targets, suggesting that splicing reprogramming may constitute an  
14 additional layer of regulations by which HTLV-1 modifies the host cell phenotype. Arguing  
15 for this, we showed that the TAX-induced splicing variant *CD44v10*, which was previously  
16 identified in circulating blood of HAM/TSP patients <sup>25</sup> and confirmed here *ex vivo* in  
17 infected CD4+ T-cell clones, contributes to modulate cell adhesion affinity *in vitro*. GO  
18 analyses of TAX splicing targets also pointed to the phosphatidylinositol signaling system  
19 and to the inositol phosphate metabolism, two processes that are particularly connected  
20 to NF- $\kappa$ B signaling and that play critical roles in oncogenesis and disease progression of  
21 malignant diseases, including ATLL <sup>43,44</sup>. This suggests that, besides its transcriptional  
22 effects, splicing regulatory functions of TAX might account for its oncogenic properties.  
23 Accordingly, a large number of TAX-regulated exons could be observed in ATLL samples,  
24 which rarely express TAX but typically exhibit NF- $\kappa$ B addiction for survival and  
25 proliferation <sup>24,45,46</sup>.

26  
27 At the molecular level, we showed that the increased chromatin occupancy of RELA upon  
28 TAX expression is not restricted to promoter regions but also occurs in the vicinity of  
29 exons that are regulated at the splicing level (Figure 4). Exons regulated by TAX, especially  
30 those localized within 1 kb of intragenic RELA binding sites, are characterized by a high  
31 GC-content, a typical feature of exons regulated by the DDX5 and DDX17 RNA helicases <sup>34</sup>  
32 (Figure S3D). Accordingly, we found that a majority of TAX-regulated exons depend on  
33 the expression of these proteins (Figure 3). A local chromatin recruitment of DDX17 and



1 RELA was validated on several TAX-regulated exons (Figure 4). More importantly we  
2 identified a confident causal relationship between the exonic tethering of RELA, the local  
3 chromatin recruitment of DDX17, and the subsequent splicing regulation via DDX17 RNA  
4 helicase activity. This catalytic activity of DDX17 is strictly required for its splicing  
5 regulatory functions (Figure 5), as previously reported <sup>34</sup>. Indeed, the RNA helicase  
6 activity of DDX5 and DDX17 has been involved in resolving RNA structures, facilitating  
7 the recognition of the 5' splice site, that can be embedded in secondary structures, and  
8 exposing RNA binding motifs to additional splicing regulators <sup>34,40,47-49</sup>. However, even  
9 though some RNA binding specificity has been reported for DDX17 <sup>50,51</sup>, these RNA  
10 helicases are devoid of a proper RNA binding domain and their activity in splicing may  
11 depend on additional factors that are able to provide target specificity. Here, we suggest  
12 that RELA may be also regarded as a DDX17 recruiter by acting as a chromatin anchor for  
13 DDX17 in the vicinity of exons dynamically selected upon NF- $\kappa$ B activation.

14  
15 The target specificity of NF- $\kappa$ B factors remains a complex question. It has been estimated  
16 that approximately 30 to 50% of genomic RELA binding sites do not harbor a typical NF-  
17  $\kappa$ B site, and that only a minority of RELA-binding events associate with transcriptional  
18 change<sup>16-19</sup>, thereby indicating that neither a consensus site nor significant NF- $\kappa$ B  
19 occupancy are sufficient criteria for defining RELA's target specificity. Here, we identified  
20 a typical  $\kappa$ B consensus motif at RELA-binding loci that are close to alternatively spliced  
21 exons but we also uncovered that weak splice sites, low MFE, and significant GC-content  
22 bias of exons likely contribute to RELA's target specificity. Because low MFE and high GC-  
23 content confer a high propensity to form stable RNA secondary structures, the recognition  
24 and the selection of such GC-rich exons with weak splice sites by the splicing machinery  
25 typically depend on RNA helicases DDX5/17 <sup>34</sup>. Based on these observations we propose  
26 that, upon TAX-induced NF- $\kappa$ B activation, RELA binds to intragenic binding consensus  
27 motifs and locally recruits DDX17. When the RELA:DDX17 complex is located at a close  
28 proximity of GC-rich exons flanked by weak splice sites, DDX17 can impact on their  
29 inclusion rate by unwinding GC-rich secondary structures of the nascent RNA transcript,  
30 and by potentially unmasking binding motifs for additional splicing regulators.

31  
32 In conclusion, our results provide conceptual advance for understanding how cell  
33 signaling pathways may drive target specificity in splicing by dynamically recruiting



1 cognate transcription factors at the vicinity of target exons that act as chromatin anchor  
2 for splicing regulators. In the context of NF- $\kappa$ B signaling, such mechanism likely has a  
3 significant impact on cell fate determination and disease development associated with  
4 HTLV-1 infection, but also on other situations linked to chronic NF- $\kappa$ B activation, as  
5 numerous human inflammatory diseases and cancer.  
6

## 1 **Acknowledgments**

2 This study makes use of data (EGAS00001001296) generated by Department of Pathology  
3 and Tumor Biology, Kyoto University <sup>24</sup>. We gratefully acknowledge support from the  
4 PSMN (Pôle Scientifique de Modélisation Numérique) of the ENS de Lyon for the  
5 computing resources. This work was supported by the Ligue Contre le Cancer (Comité de  
6 la Savoie, de la Drome et du Rhône), the Fondation ARC (ARC PJA20151203399), and the  
7 Agence Nationale pour la Recherche (program EPIVIR and CHROTOPAS). L.B.A was  
8 supported by Ligue Contre le Cancer. G.G was support by ANR CHROTOPAS. M.T. was  
9 supported by a bursary from the French Ministry of Higher Education and Science. F.M.,  
10 C.F.B, and D.A. were supported by INSERM. E.W. was supported by Hospices Civils de Lyon  
11 and Lyon I University (France).

12

## 13 **Author Contributions**

14 Conceptualization, L.B.A., D.A. and F.M.; Resources, A.G. and E.W.; Experiments, L.B.A.,  
15 M.T., and G.G.; Technical Support, E.C. and M.B.; Bioinformatic, J.B.C., H.P. and N.F., Formal  
16 Analysis, L.B.A., M.T., G.G. and F.M.; Supervision, D.A. and F.M.; Funding Acquisition, C.F.B.,  
17 D.A. and F.M.; Writing – Original Draft, F.M.; Writing – Review and Editing, L.B.A, M.T., G.G.,  
18 C.F.B., D.A. and F.M.

19

## 20 **Declaration of Interests**

21 The authors declare no competing interest.

22

23

## 1 References

- 2 1. Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K. & Uchino, H. Adult T-cell leukemia:  
3 clinical and hematologic features of 16 cases. *Blood* **50**, 481-92 (1977).
- 4 2. Gessain, A. et al. Antibodies to human T-lymphotropic virus type-I in patients with  
5 tropical spastic paraparesis. *Lancet* **2**, 407-10 (1985).
- 6 3. Vernin, C. et al. HTLV-1 bZIP factor HBZ promotes cell proliferation and genetic  
7 instability by activating OncomiRs. *Cancer Res* **74**, 6082-93 (2014).
- 8 4. Thenoz, M. et al. HTLV-1-infected CD4+ T-cells display alternative exon usages that  
9 culminate in adult T-cell leukemia. *Retrovirology* **11**, 119 (2014).
- 10 5. Naftelberg, S., Schor, I.E., Ast, G. & Kornblihtt, A.R. Regulation of alternative splicing  
11 through coupling with transcription and chromatin structure. *Annu Rev Biochem*  
12 **84**, 165-98 (2015).
- 13 6. Herzog, L., Ottoz, D.S.M., Alpert, T. & Neugebauer, K.M. Splicing and transcription  
14 touch base: co-transcriptional spliceosome assembly and function. *Nat Rev Mol Cell*  
15 *Biol* **18**, 637-650 (2017).
- 16 7. Matsuoka, M. & Jeang, K.T. Human T-cell leukaemia virus type 1 (HTLV-1)  
17 infectivity and cellular transformation. *Nat Rev Cancer* **7**, 270-80 (2007).
- 18 8. Sun, S.C. & Yamaoka, S. Activation of NF-kappaB by HTLV-I and implications for cell  
19 transformation. *Oncogene* **24**, 5952-64 (2005).
- 20 9. Liu, T., Zhang, L., Joo, D. & Sun, S.C. NF-kappaB signaling in inflammation. *Signal*  
21 *Transduct Target Ther* **2**(2017).
- 22 10. Hoesel, B. & Schmid, J.A. The complexity of NF-kappaB signaling in inflammation  
23 and cancer. *Mol Cancer* **12**, 86 (2013).
- 24 11. Harhaj, E.W. & Giam, C.Z. NF-kappaB signaling mechanisms in HTLV-1-induced  
25 adult T-cell leukemia/lymphoma. *FEBS J* (2018).
- 26 12. Harhaj, E.W. & Sun, S.C. IKKgamma serves as a docking subunit of the IkappaB  
27 kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus  
28 Tax protein. *J Biol Chem* **274**, 22911-4 (1999).
- 29 13. Jin, D.Y., Giordano, V., Kibler, K.V., Nakano, H. & Jeang, K.T. Role of adapter function  
30 in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus  
31 type I Tax interacts directly with IkappaB kinase gamma. *J Biol Chem* **274**, 17402-  
32 5 (1999).
- 33 14. Lacoste, J., Lanoix, J., Pepin, N. & Hiscott, J. Interactions between HTLV-I Tax and  
34 NF-kappa B/Rel proteins in T cells. *Leukemia* **8 Suppl 1**, S71-6 (1994).
- 35 15. Suzuki, T., Hirai, H. & Yoshida, M. Tax protein of HTLV-1 interacts with the Rel  
36 homology domain of NF-kappa B p65 and c-Rel proteins bound to the NF-kappa B  
37 binding site and activates transcription. *Oncogene* **9**, 3099-105 (1994).
- 38 16. Martone, R. et al. Distribution of NF-kappaB-binding sites across human  
39 chromosome 22. *Proc Natl Acad Sci U S A* **100**, 12247-52 (2003).
- 40 17. Lim, C.A. et al. Genome-wide mapping of RELA(p65) binding identifies E2F1 as a  
41 transcriptional activator recruited by NF-kappaB upon TLR4 activation. *Mol Cell*  
42 **27**, 622-35 (2007).
- 43 18. Zhao, B. et al. The NF-kappaB genomic landscape in lymphoblastoid B cells. *Cell*  
44 *Rep* **8**, 1595-606 (2014).
- 45 19. Xing, Y., Yang, Y., Zhou, F. & Wang, J. Characterization of genome-wide binding of  
46 NF-kappaB in TNFalpha-stimulated HeLa cells. *Gene* **526**, 142-9 (2013).
- 47 20. Kolovos, P. et al. Binding of nuclear factor kappaB to noncanonical consensus sites  
48 reveals its multimodal role during the early inflammatory response. *Genome Res*  
49 **26**, 1478-1489 (2016).

- 1 21. Farnham, P.J. Insights from genomic profiling of transcription factors. *Nat Rev*
- 2 *Genet* **10**, 605-16 (2009).
- 3 22. Lambert, M.P. et al. The RNA helicase DDX17 controls the transcriptional activity
- 4 of REST and the expression of proneural microRNAs in neuronal differentiation.
- 5 *Nucleic Acids Res* (2018).
- 6 23. Benoit-Pilven, C. et al. Complementarity of assembly-first and mapping-first
- 7 approaches for alternative splicing annotation and differential analysis from
- 8 RNAseq data. *Sci Rep* **8**, 4307 (2018).
- 9 24. Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia/lymphoma.
- 10 *Nat Genet* **47**, 1304-15 (2015).
- 11 25. Matsuoka, E. et al. CD44 splice variant involvement in the chronic inflammatory
- 12 disease of the spinal cord: HAM/TSP. *J Neuroimmunol* **102**, 1-7 (2000).
- 13 26. Mizuguchi, M. et al. Induction of Cell Death in Growing Human T-Cells and Cell
- 14 Survival in Resting Cells in Response to the Human T-Cell Leukemia Virus Type 1
- 15 Tax. *PLoS One* **11**, e0148217 (2016).
- 16 27. Harhaj, E.W. & Giam, C.Z. NF-kappaB signaling mechanisms in HTLV-1-induced
- 17 adult T-cell leukemia/lymphoma. *FEBS J* **285**, 3324-3336 (2018).
- 18 28. Weimann, T.K., Wagner, C., Goos, M. & Wagner, S.N. CD44 variant isoform v10 is
- 19 expressed on tumor-infiltrating lymphocytes and mediates hyaluronan-
- 20 independent heterotypic cell-cell adhesion to melanoma cells. *Exp Dermatol* **12**,
- 21 204-12 (2003).
- 22 29. Gao, L. & Harhaj, E.W. HSP90 protects the human T-cell leukemia virus type 1
- 23 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-kappaB
- 24 activation and HTLV-1 replication. *J Virol* **87**, 13640-54 (2013).
- 25 30. Robek, M.D. & Ratner, L. immortalization of CD4(+) and CD8(+) T lymphocytes by
- 26 human T-cell leukemia virus type 1 Tax mutants expressed in a functional
- 27 molecular clone. *J Virol* **73**, 4856-65 (1999).
- 28 31. Harhaj, E.W., Good, L., Xiao, G. & Sun, S.C. Gene expression profiles in HTLV-I-
- 29 immortalized T cells: deregulated expression of genes involved in apoptosis
- 30 regulation. *Oncogene* **18**, 1341-9 (1999).
- 31 32. Smith, M.R. & Greene, W.C. Identification of HTLV-I tax trans-activator mutants
- 32 exhibiting novel transcriptional phenotypes. *Genes Dev* **4**, 1875-85 (1990).
- 33 33. Xiao, G., Harhaj, E.W. & Sun, S.C. Domain-specific interaction with the I kappa B
- 34 kinase (IKK)regulatory subunit IKK gamma is an essential step in tax-mediated
- 35 activation of IKK. *J Biol Chem* **275**, 34060-7 (2000).
- 36 34. Dardenne, E. et al. RNA helicases DDX5 and DDX17 dynamically orchestrate
- 37 transcription, miRNA, and splicing programs in cell differentiation. *Cell Rep* **7**,
- 38 1900-13 (2014).
- 39 35. Geissler, V., Altmeyer, S., Stein, B., Uhlmann-Schiffler, H. & Stahl, H. The RNA
- 40 helicase Ddx5/p68 binds to hUpf3 and enhances NMD of Ddx17/p72 and Smg5
- 41 mRNA. *Nucleic Acids Res* **41**, 7875-88 (2013).
- 42 36. Ponta, H., Sherman, L. & Herrlich, P.A. CD44: from adhesion molecules to signalling
- 43 regulators. *Nat Rev Mol Cell Biol* **4**, 33-45 (2003).
- 44 37. Bailey, T.L. et al. MEME SUITE: tools for motif discovery and searching. *Nucleic*
- 45 *Acids Res* **37**, W202-8 (2009).
- 46 38. Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL
- 47 effector-based constructs for DNA targeting. *Nucleic Acids Res* **39**, e82 (2011).
- 48 39. Laurent, F.X. et al. New function for the RNA helicase p68/DDX5 as a modifier of
- 49 MBNL1 activity on expanded CUG repeats. *Nucleic Acids Res* **40**, 3159-71 (2012).

- 1 40. Kar, A. et al. RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating  
2 a stem-loop structure at the 5' splice site. *Mol Cell Biol* **31**, 1812-21 (2011).
- 3 41. Dardenne, E. et al. Splicing switch of an epigenetic regulator by RNA helicases  
4 promotes tumor-cell invasiveness. *Nat Struct Mol Biol* **19**, 1139-46 (2012).
- 5 42. Rosewick, N. et al. Cis-perturbation of cancer drivers by the HTLV-1/BLV  
6 proviruses is an early determinant of leukemogenesis. *Nat Commun* **8**, 15264  
7 (2017).
- 8 43. Nakahata, S. et al. Loss of NDRG2 expression activates PI3K-AKT signalling via  
9 PTEN phosphorylation in ATLL and other cancers. *Nat Commun* **5**, 3393 (2014).
- 10 44. Bai, D., Ueno, L. & Vogt, P.K. Akt-mediated regulation of NFkappaB and the  
11 essentialness of NFkappaB for the oncogenicity of PI3K and Akt. *Int J Cancer* **125**,  
12 2863-70 (2009).
- 13 45. Yamagishi, M. et al. Polycomb-mediated loss of miR-31 activates NIK-dependent  
14 NF-kappaB pathway in adult T cell leukemia and other cancers. *Cancer Cell* **21**,  
15 121-35 (2012).
- 16 46. Mahgoub, M. et al. Sporadic on/off switching of HTLV-1 Tax expression is crucial  
17 to maintain the whole population of virus-induced leukemic cells. *Proc Natl Acad*  
18 *Sci U S A* **115**, E1269-E1278 (2018).
- 19 47. Sithole, N., Williams, C.A., Vaughan, A.M., Kenyon, J.C. & Lever, A.M.L. DDX17  
20 Specifically, and Independently of DDX5, Controls Use of the HIV A4/5 Splice  
21 Acceptor Cluster and Is Essential for Efficient Replication of HIV. *J Mol Biol* **430**,  
22 3111-3128 (2018).
- 23 48. Lin, C., Yang, L., Yang, J.J., Huang, Y. & Liu, Z.R. ATPase/helicase activities of p68  
24 RNA helicase are required for pre-mRNA splicing but not for assembly of the  
25 spliceosome. *Mol Cell Biol* **25**, 7484-93 (2005).
- 26 49. Camats, M., Guil, S., Kokolo, M. & Bach-Elias, M. P68 RNA helicase (DDX5) alters  
27 activity of cis- and trans-acting factors of the alternative splicing of H-Ras. *PLoS*  
28 *One* **3**, e2926 (2008).
- 29 50. Moy, R.H. et al. Stem-loop recognition by DDX17 facilitates miRNA processing and  
30 antiviral defense. *Cell* **158**, 764-777 (2014).
- 31 51. Mori, M. et al. Hippo signaling regulates microprocessor and links cell-density-  
32 dependent miRNA biogenesis to cancer. *Cell* **156**, 893-906 (2014).
- 33 52. Delebecque, F., Pramberger, K., Prevost, M.C., Brahic, M. & Tangy, F. A chimeric  
34 human T-cell lymphotropic virus type 1 with the envelope glycoprotein of Moloney  
35 murine leukemia virus is infectious for murine cells. *J Virol* **76**, 7883-9 (2002).
- 36 53. Mallinjoud, P. et al. Endothelial, epithelial, and fibroblast cells exhibit specific  
37 splicing programs independently of their tissue of origin. *Genome Res* **24**, 511-21  
38 (2014).
- 39 54. Anders, S., Pyl, P.T. & Huber, W. HTSeq--a Python framework to work with high-  
40 throughput sequencing data. *Bioinformatics* **31**, 166-9 (2015).
- 41 55. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and  
42 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 43 56. Messeguer, X. et al. PROMO: detection of known transcription regulatory elements  
44 using species-tailored searches. *Bioinformatics* **18**, 333-4 (2002).
- 45 57. Yeo, G. & Burge, C.B. Maximum entropy modeling of short sequence motifs with  
46 applications to RNA splicing signals. *J Comput Biol* **11**, 377-94 (2004).
- 47 58. Barrett, T. et al. NCBI GEO: archive for functional genomics data sets--update.  
48 *Nucleic Acids Res* **41**, D991-5 (2013).

- 1 59. Consortium, E.P. An integrated encyclopedia of DNA elements in the human  
2 genome. *Nature* **489**, 57-74 (2012).
- 3 60. Zheng, R. et al. Cistrome Data Browser: expanded datasets and new tools for gene  
4 regulatory analysis. *Nucleic Acids Res* (2018).
- 5 61. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat*  
6 *Methods* **9**, 357-9 (2012).
- 7 62. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137  
8 (2008).
- 9 63. Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing  
10 genomic features. *Bioinformatics* **26**, 841-2 (2010).
- 11 64. Zhu, L.J., Holmes, B.R., Aronin, N. & Brodsky, M.H. CRISPRseek: a bioconductor  
12 package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing  
13 systems. *PLoS One* **9**, e108424 (2014).
- 14
- 15

1 **Supplementary data**

2 **Table S1: Whole gene expression and alternative splicing changes upon TAX**  
3 **expression.** Whole gene expression threshold was set to  $\log_2FC=0.6$ ,  $p<0.05$ . For  
4 differential splicing, deltaPsi threshold was set to 1.1  $p<0.05$  (Fisher test). TAX-induced  
5 splicing regulations identified in RNA-seq datasets derived from carriers and ATLL  
6 samples (EGAS00001001296). Alternative splicing profiles of each clinical sample was  
7 assessed using Farline analysis with peripheral blood CD4+ T-cells used as control. The  
8 table lists 452 TAX-induced splicing regulations identified at least once across 56 clinical  
9 samples.

10

11 **Table S2: sequence features of exons regulated by TAX**

12

13 **Table S3: genes modified in splicing by TAX in a DDX5/17-dependent manner.**

14 TAX splicing targets responsive to DDX5/17 were attributed to splicing events lost upon  
15 DDX5/17 depletion.

16

17 **Table S4: list of oligonucleotides, siRNA, sgRNA and TALE sequences**



## 1 **Methods**

### 2 *Cell Culture and Transfections*

3 Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll separation of whole  
4 blood of HTLV-1 infected individuals. T-cell limiting dilution cloning was performed as  
5 previously described <sup>4</sup>. The human embryonic kidney 293T-LTR-GFP cells <sup>52</sup>, which  
6 contain an integrated GFP reporter gene under the control of the TAX-responsive HTLV-  
7 1 LTR, were cultured in DMEM+Glutamax medium supplemented with decomplexed  
8 10% FBS and 1% penicilline/streptomycine. This cell line was used to measure  
9 transfection efficiency in TAX and TAX M22 conditions. In standard transfection  
10 experiments, siRNAs (Table S4) and/or expression vectors (pSG5M empty, pSG5M-TAX-  
11 WT, pSG5M-M22) were mixed with JetPrime (Polyplus-Transfection) following the  
12 manufacturer's instructions and cells were harvested 48h after transfection. TNF $\alpha$   
13 exposure consisted in treating cells with 10ng/ml of TNF $\alpha$  for 24 hours.

14

### 15 *Cell-adhesion assays*

16 Culture plates were prepared by coating with 40  $\mu$ g/ml hyaluronic acid from human  
17 umbilical cord (Sigma) and 25  $\mu$ g/ml type IV collagen from human placenta (Sigma)  
18 overnight at 4°C. Non-specific binding sites were blocked for 1 h with PBS containing 1  
19 mg/ml heat-denatured BSA. After three washes with PBS,  $5 \times 10^4$  cells transiently  
20 transfected with pSG5M-TAX vector or its empty control were added at 48h post-  
21 transfection. Cell adhesion was allowed to proceed for 20 min at room temperature. Non-  
22 adherent cells were removed with 3 PBS washes, and adherent cells were quantified. All  
23 experiments were done in triplicate.

24

### 25 *Western Blot*

26 Cells were washed twice with 1X PBS and total proteins were directly extracted in RIPA  
27 buffer (50mM Tris HCL pH 7.4, 50 mM NaCl, 2mM EDTA, 0.1% SDS). A total of 20  $\mu$ g of  
28 whole cell proteins were separated on a NuPAGE™ 4-12% Bis-Tris Protein Gels and  
29 transferred on a nitrocellulose membrane using Trans-Blot® Turbo™ Blotting System.  
30 Membranes were saturated with 5% milk and incubated overnight at 4°C with the primary  
31 antibodies against RELA (sc-109, Santa Cruz), Tax (1A3, Covalab), DDX17 (ProteinTech),  
32 DDX5 (ab10261 Abcam), Actin (sc-1616, SantaCruz). After three washes with 1x TBS-  
33 Tween, membranes were incubated 1h at room temperature with the secondary



1 antibodies conjugated with the HRP enzyme and washed 3 times as above. Finally, the  
2 HRP substrate (GE Helathcare) was applied to the membrane for 5 minutes and the  
3 chemiluminescence was read on Chemidoc (Biorad).

4

#### 5 *Co-immunoprecipitation*

6 Cells were harvested in IP lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA,  
7 1% NP40, 10% Glycerol). Extracts were incubated overnight with 5 µg of antibodies  
8 recognizing either RELA (C20 sc-372, Santa Cruz), Tax (1A3, Covalab), DDX17  
9 (ProteinTech) in the presence of 30 µL Dynabeads® Protein A/G (Thermo Fisher).  
10 Isotype IgG rabbit (Invitrogen) or mouse (Santa Cruz) was also used as negative control.  
11 The immunoprecipitated complexes were washed three times with IP lysis buffer.

12

#### 13 *Chromatin Immunoprecipitation*

14 A total of  $10^7$  cells were crosslinked with 1% formaldehyde for 10 minutes at room  
15 temperature. Crosslinking was quenched by addition of 0.125 M glycine. Nuclei were  
16 isolated by sonication using a Covaris S220 (2 min, Peak Power: 75; Duty Factor: 2;  
17 Cycles/burst: 200), pelleted by centrifugation at 3,000 rpm for 5 min at 4°C, washed once  
18 with FL buffer (5 mM HEPES pH 8.0, 85 mM KCl, 0.5% NP40) and resuspended in 1 mL  
19 shearing buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 2 mM EDTA, 0.1% SDS). Chromatin  
20 was sheared in order to obtain fragments ranging from 200 to 800 bp using Covaris S220  
21 (20 min, Peak Power: 140; Duty Factor: 5; Cycles/burst: 200). Chromatin was next  
22 immunoprecipitated overnight at 4°C with 5 µg of antibodies: RELA (C20 sc-372, Santa  
23 Cruz), DDX17 (19910-1-AP, ProteinTech) and V5 (AB3792, Millipore). Then, 30 µL  
24 Dynabeads® Protein A/G (Thermo Fisher) were added. Complexes were washed using 5  
25 different buffers : Wash 1 ( 1 % Triton, 0.1 % NaDOC , 150mM NaCl , 10mM Tris HCL pH8)  
26 , Wash 2 ( 1 % NP-40, 1 % NaDOC , 150mM KCl , 10mM Tris HCL pH8 ) , Wash 3 ( 0.5 %  
27 Triton, 0.1 % NaDOC , 500mM NaCl , 10mM Tris HCL pH8), Wash 4 ( 0,5% NP-40 , 0.5 %  
28 NaDOC , 250mM LiCl , 20mM TRIS.Cl pH8 , 1mM EDTA ) , Wash 5 ( 0.1 % NP-40, 150mM  
29 NaCl , 20mM Tris HCL pH8,1mM EDTA). The immunoprecipitated chromatin was purified  
30 by phenol-chloroform extraction and quantitative PCR was performed using Rotor-Gene  
31 3000 cyler (Corbett) or LightCycler 480 II (Roche, Mannheim, Germany). Values were  
32 expressed relative to the signal obtained for the immunoprecipitation with control IgG.  
33 Primers used for CHIP experiments were designed in exon/intron junction (Table S4). For

1 TALE ChIP experiment, DDX17 and RelA enrichment were normalized to the signal  
2 observed with V5 antibody corresponding to TALE recruitment. Then, the TALE GFP  
3 condition was used as control and set to 1.

4

#### 5 *RNA extraction, classical PCR and Real-time quantitative PCR.*

6 Total RNAs were extracted using TRIzol (Invitrogen). RNAs (2.5  $\mu$ g) were retro-  
7 transcribed with Maxima First Strand cDNA Synthesis Kit after treatment with dsDNase  
8 (Thermo Scientific) following the manufacturer's instructions. PCRs were performed  
9 using 7.5 ng of cDNAs with GoTaq polymerase (Promega, Madison, WI, USA). PCR  
10 products were separated by ethidium bromide-labeled agarose gel electrophoresis. Band  
11 intensity was quantified using the ImageLab software (Bio-Rad). Quantitative PCR was  
12 then performed using 5 ng of cDNAs with SYBR® Premix Ex Taq™ II (Tli RNaseH Plus)  
13 on LightCycler 480 II. Relative level of the target sequence was normalized using the 18S  
14 or GAPDH gene expression ( $\Delta$ Ct) and controls were set to 1( $\Delta\Delta$ Ct). We calculated the  
15 inclusion rate of alternative exons using the following method:  $2^{-\Delta\Delta$ Ct} (included  
16 exon)/ $2^{-\Delta\Delta$ Ct} (constitutive exon). The oligonucleotide sequences used are listed in Table  
17 S4.

18

#### 19 *RNA-seq and bio-informatic analysis*

20 RNA-seq analyses were performed as previously described<sup>22</sup>. Briefly, poly-A transcripts  
21 were extracted from 293T-LTR-GFP cells transfected with pSG5M-Tax or pSG5M empty  
22 vectors and knockdown or not for DDX5-17. RNA-seq libraries were generated at the Aros  
23 Applied Biotechnology (Aarhus, Denmark) using Stranded mRNA Sample Prep kit  
24 (Illumina) and sequenced using the illumina HiSeq 2500 technology. Each sample have in  
25 average  $6.10^7$  of paired-end pairs of reads. These RNA-seq data were analyzed using  
26 FaRLine, a computational program dedicated to analyzing alternative splicing with  
27 FasterDB database<sup>23,53</sup>. The gene expression level in each sample was calculated with  
28 HTSeq-count (v0.7.2)<sup>54</sup> and differential expression between conditions was computed  
29 with DESeq2 (v1.10.1) ( $\text{abs}(\log_2\text{FoldChange}) \geq 0.4$ ,  $p\text{values} \leq 0.05$ )<sup>55</sup>. In silico screening  
30 of NF- $\kappa$ B responsive elements in the CD44 promoter sequence was carried out via PROMO  
31 database (based on TRANSFAC v8.3)<sup>56</sup>. The MEME-ChIP suite was used to discover the  
32 regulatory motifs in the NF- $\kappa$ B ChIP-seq data<sup>37</sup>.

1 For the prediction of splice site strength, scores were computed using MaxEntScan<sup>57</sup> for  
2 sequence (3 bases in the exon and 6 bases in the intron for 5' splice sites; 20 bases in the  
3 intron and 3 bases in the exon for 3' splice sites) covering both sides of the splicing site.  
4 MaxEntScan uses Maximum Entropy Models (MEMs) to compute log odds ratios. The  
5 minimum free energy was computed from exon-intron junction sequences using RNAFold  
6 from the ViennaRNA package (v 2.4.1; [http://rna.tbi.univie.ac.at/cgi-](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi)  
7 [bin/RNAWebSuite/RNAfold.cgi](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi)). Analyzed sequences include 25 nucleotides within the  
8 intron and 25 nucleotides within the exon. The GC content was calculated for exons  
9 defined in FasterDB<sup>53</sup>.

10

11 The distribution of RELA peaks across alternative and constitutive exons, and the average  
12 distance between RELA peaks and TAX exon targets was measured using ChIP-seq  
13 datasets from GEO<sup>58</sup>, ENCODE<sup>59</sup> and CISTROME<sup>60</sup> databases: from GEO GSE63736,  
14 GSM1239484, GSM486271, GSM486293, GSM486298, GSM486318, GSM847876,  
15 GSM847877, GSM2394419, GSM2394421, GSM2394423, from ENCODE ENCF002CPA,  
16 ENCF002CQB, ENCF002CQJ, ENCF002CQN, ENCF002CQGA and from CISTROME  
17 53597, 5388, 5389, 4940, 36310, 36316, 4971. For another GEO dataset, GSM2628088,  
18 reads were mapped to the hg19 build of the human genome with Bowtie2<sup>61</sup> and RelA  
19 peaks were identified with Macs2<sup>62</sup>. Alternative and Constitutive spliced exons were  
20 obtained from FasterDB<sup>53</sup>. In order to focus on intragenic RELA peaks, we used the  
21 bedtools<sup>63</sup> intersect command to remove all intergenic RELA peaks and all RELA peaks  
22 localized on first exon (or at least at less than 500nt) for each gene. A Perl script was  
23 specifically created to measure the distance between RELA peaks and TAX-regulated  
24 exons. Briefly, RELA peaks and exons are provided as BED files and the script reports for  
25 each exon the distance in nucleotides of the nearest RELA peak. Closest peak distances  
26 from the 710 TAX-regulated exon-cassettes were compared to closest peak distances  
27 from 710 exons chosen by chance ( $10^5$  runs).

28

### 29 *TALE design and construct*

30 The TALE constructs were obtained from ThermoFisher Scientific. TALEs were  
31 constructed using the Golden Gate Assembly method as previously described<sup>38</sup>. The RVDs  
32 HD, NI, NG and NN were chosen to specifically recognize the nucleotides C, A, T and G,  
33 respectively. The TALE targeting CD44 v10 sequence was 5' TCCAACCTCTAATGTCAATC 3'.

1 This TALE construct was fused to a V5 sequence and a SV40 NLS at its 5' end and cloned  
2 in the NotI-HindIII fragment of the pXJ41 backbone plasmid. DDX17-WT and DDX17-  
3 K142R cDNA were obtained by PCR from pcDNA3-HA-DDX17 and pcDNA3-HA-DDX17-  
4 K142R and were cloned in the HindIII-BglII fragment in the MCS downstream to the TALE  
5 sequence. The *RELA* cDNA was amplified from a library of cDNA of 293T-LTR-GFP cells  
6 and was cloned in the HindIII-BamHI fragment.

7


### 8 *CRISPR design and construct*

9 The sequence-specific sgRNA for site-specific interference of genomic targets were  
10 designed using CRISPRseek R package<sup>1</sup>, and sequences were selected to minimize off-  
11 target effect<sup>64</sup>. Two complementary oligonucleotides were annealed and cloned into BbsI  
12 site of pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene plasmid #62988) for co-expression  
13 with Cas9 using 5U of T4 DNA ligase, T4 DNA ligase buffer (1X) (Roche). 293T-LTR-GFP  
14 cells were transfected with the mix of equimolar ratio of PX459-sgRNA1 and PX459-  
15 sgRNA2 (Table S4). At 24h post-transfection, the medium was changed and 1µg/ml  
16 puromycin was added for selection and cells were cloned by serial dilution method.

17


### 18 **ACCESSION NUMBERS**

19 The RNA-Seq data have been deposited on NCBI GEO under the accession number  
20 GSE123752.



**Figure 1: TAX induces alternative splicing modifications independently of its transcriptional effects.**


(A) Genes regulated at the steady-state expression level and at the splicing level upon TAX expression. The significance thresholds were typically set to 10% for  $\Delta$ PSI (differential percentage of spliced-in sequence) and 0.6 for  $\log_2$ - gene expression changes ( $p$ -val<0.05, Fisher's exact test), respectively. (B) Different alternative splicing events induced by TAX: alternative acceptor (acc), alternative donor (don), exon skipping (ES), multi-exon skipping (MES), multi-exclusive exon skipping (MEx). (C) Validation of alternative splicing predictions by RT-PCR (35 cycles of PCR). The exon number is indicated in red. CD44 full variants (Ev\*) were assessed using primers C13 and C12A (Figure S4). (D) Exon-based hierarchical clustering. Kruskal-Wallis ANOVA ( $p$ -val<0.05) was carried out with Mev4.0 software (<http://www.tm4.org/>) using the PSI values of exons that share similar regulations upon TAX and in clinical samples (EGAS00001001296). Only the most significant exon regulations are presented. (E) Gene ontology analysis (DAVID) of TAX splicing and transcriptional targets.



**Figure 2: Physical interactions between TAX, RELA and DDX17 in an NF- $\kappa$ B dependent manner.**


(A) Mean average plot ( $n=3$ ,  $p<0.05$ ) of cellular gene expressions upon TAX. Each gene is plotted according to its expression level ( $\text{Log}_{10}(\text{BaseMean})$  from DESeq2 analysis) and to fold change ( $\text{Log}_2\text{-FC}$ ) upon TAX. Red dots show significant gene expression changes ( $\text{Log}_2\text{-FC}>0.6$ ,  $p\text{-val}<0.05$ , Fisher's exact test). Black dots highlight genes encoding splicing factors. DDX5 and DDX17 are indicated. (B) Immunoprecipitation assays (IP) were carried out using isotype IgG or anti-DDX17 (B and G), anti-RELA (E and G) and anti-TAX (C and G) antibodies, followed by immunoblotting (IB) with indicated antibodies. (D) Western blot analysis of TAX and M22 expression 48h post-transfection. (E) RNA-free IP assays. (F) RNA-free IP assays. (G) TNF $\alpha$  exposure of M22 expressing cells promotes RELA-DDX17 interactions. (H) Model of NF- $\kappa$ B-dependent interplay between TAX, RELA and DDX17.





**Figure 3: DDX5/17 regulates TAX splicing targets in an NF-κB-dependent manner.**


(A) Western blot analysis of DDX5 and DDX17 expression in cells expressing or not TAX and depleted or not of DDX5 and DDX17 by siRNA. (B) Western blot analysis of RELA and β-actin upon TAX expression and siRNA-DDX5/17 delivery. (C) Splicing events modified upon the depletion of DDX5/17 in TAX positive cells. The significant threshold was set to  $\geq 2$  in comparisons between TAXvsCTL and TAXsiDDX5/17vsCTL. (D) Validation of alternative splicing predictions of a set of TAX- and DDX5/17-regulated exons. Histograms represent the results of exon specific quantitative RT-PCR measurements computed as a relative exon inclusion (alternatively spliced exon vs constitutive exon reflecting the total gene expression level) from three biological replicates  $\pm$  s.d.. All of these genes but MYCBP2 were unmodified at the whole transcript level upon TAX expression (Figure S2C).



**Figure 4: RELA locally recruits DDX17 at the genomic target exons for regulating splicing.**


(A) Schematic representation of the human CD44 gene. Black and white boxes represent constitutive and alternative exons as previously annotated (50), respectively. The orange box represents the  $\kappa$ B site localized at -218 bp from the TSS and the 40 bp fragment deleted by CRISPR/Cas9 in CD44 $\Delta$ kB cells. (B) qChIP analysis of RELA occupancy across the promoter, the exon v10, and the constitutive exon E16 of CD44. The RELA enrichment is expressed as the fold increase in signal relative to the background signal obtained using a control IgG. (C) Relative exon inclusion of CD44 exon v10 were quantified by qRT-PCR in parental cells and its CD44 $\Delta$ kB counterparts. The histogram shows mean  $\pm$  sd of three independent experiments. (D) Bootstrapped distribution of median distance between intragenic RELA peaks and either TAX-regulated exons (red line, 1079 bp) or randomly chosen exons (10000 repetitions) (blue).  $p$ val : sample t-test (E) Consensus de novo motif for RELA binding sites <1kbp of TAX regulated exons. (F) Strength and minimum free energy (MFE) of 3' and 5' splice sites, and GC content (G) of TAX-regulated exons localized at <1kbp of RELA binding site. The exons of FasterDB database were used as control. (H) Relative RELA and DDX17 occupancies at TAX-regulated exons in control and TAX expressing cells. For each gene, the binding of RELA or DDX17 to the regulated exon is represented as a comparison to the binding to a neighbouring constitutive exon (\* $p$ -val $\leq$ 0.05). (I) Relative RELA occupancy at TAX-regulated exons in cells treated with DDX5/17-specific siRNA and expressing or not TAX. Details are as in D. (\* $p$  $\leq$ 0.05, \*\*\* $p$  $\leq$ 0.001, \*\*\*\* $p$  $\leq$ 0.0001, Mann-Whitney test)






**Figure 5: Chromatin and splicing regulation upon TALE-mediated tethering of RELA and DDX17.**

(A) The TALE domain was designed to bind the v10 exon of CD44 and fused to either GFP (A-C), RELA (A), DDX17 (B) or its helicase-deficient mutant DDX17\_K142R (C). The effect of TALEs on RELA and DDX17 chromatin enrichment (left panels) and on the relative v10 exon inclusion (right panels) was monitored by qChIP and qRT-PCR, respectively. Results were normalized to measures obtained in TALE-GFP assays. Mean  $\pm$  sd of three independent experiments are shown (\*p-val<0.05).




**Figure S1: TAX-induced alternative splicing of CD44 in vivo and in vitro.**

(A) Expression of the splicing variant CD44v10 in HTLV-1 positive and negative cellular clones T-CD4<sup>+</sup> derived from HAM/TSP patients (7 cellular clones in each category). CD44v10 mRNA were quantified by qRT-PCR from total RNA extracts. Median  $\pm$ SD for non-infected vs infected clones were  $11.1 \pm 6.87$  vs  $3.7 \pm 3.57$ ; Mann Whitney test,  $p=0.047$ . (B) Positive correlation between TAX and CD44v10 mRNA expression in 7 infected CD4<sup>+</sup> T-cell clones (Pearson correlation test). (C) qRT-PCR analysis of exon inclusion rate of CD44 exon v10 in 293 T-cells transiently transfected with pSG5M-TAX, pSG5M-M22 and empty pSG5M constructs. The relative exon inclusion of v10 corresponds to normalized v10 versus exon E16 (constitutive exon) expression levels. (D) Cell adhesion properties of cells transiently transfected with control vector, pSG5M-TAX and pCEP4-CD44V10 on plate surfaces coated with Hyaluronic acid and type IV Collagen. Histograms represent means  $\pm$  s.d. of three independent experiments.



**Figure S2: DDX5/17 expression regulate TAX splicing targets.**


(A) Bootstrapped distribution of DDX5/17 sensitive TAX-regulated exons and 648 randomly chosen exons (10000 repetitions) among overall expressed exons (blue). One Sample t-test  $p = 2.2e-16$ . (B) Validation of RNA-seq data using exon specific RT-PCR. (C) Fold change in gene expression of TAX-regulated exons responsive to DDX5/17 upon TAX expression. Values were obtained from DESeq2 analysis of RNA-seq data and expressed as Log<sub>2</sub>(FoldChange). Histograms represent means  $\pm$  s.d. of three independent experiments. (\*)  $p$ -val<0.05 (Mann Whitney test).



**Figure S3: Chromatin tethering of RELA and DDX17 regulates alternative splicing.**

(A) TAX-induced exon inclusion of CD44 exon v10 relies on NF- $\kappa$ B activation. 293T-LTR-GFP cells were transiently transfected with the TAX vector along with the IkBSR expression vector and the corresponding empty control vectors. The inclusion rate of exon v10 was quantified by qRT-PCR. Histograms represent means  $\pm$  s.d. of three independent experiments. (\*)  $p < 0.05$  (Mann-Whitney test). (B) Distribution of constitutive and alternative exons in RELA-enriched intragenic regions (3 kb). ChIP-seq datasets were analysed as detailed in method section. We excluded RELA peaks localized in intergenic regions and exons linked to specific events like promoters, alternative first/last and mutually exclusive exons. The groups “Constitutive exons” and “Alternative exons” contained 41873 and 103000 exons, respectively. The window was fixed to 3 kb upstream and downstream of each exon coordinates. P-value was calculated using the Mann-Whitney test.

A



**Figure S4: Nested RT-PCR analysis of CD44 transcripts expressed in TALE assays and in cells expressing or not TAX.**

Oligonucleotides were previously described (36). The first round of amplification consisted in 15 cycles of PCR with the primers C13 and C12A, the second round consisted in 35 cycles with primers pv10 and C2A. Final PCR products were resolved on Agarose gel (1%).